Related Experiment Video

Updated: Dec 21, 2025

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

17.0K

Epi-drugs as triple-negative breast cancer treatment

Mouhamed Idrissou1,2, Anna Sanchez1,2, Frédérique Penault-Llorca2,3

  • 1Department of Oncogenetics, Centre Jean Perrin, CBRV, 28 place Henri-Dunant, Clermont-Ferrand 63001, France.

Epigenomics
|May 13, 2020
PubMed

Insights

Triple-negative breast cancer (TNBC) lacks targeted therapies. Epigenetic drugs (epi-drugs) show promise by modulating gene expression, offering a new treatment avenue for TNBC patients.

Area of Science:

  • Oncology
  • Epigenetics
  • Pharmacology

Background:

  • Triple-negative breast cancer (TNBC) presents a poor prognosis due to the absence of estrogen receptors, progesterone receptors, and HER2.
  • The limited therapeutic options for TNBC necessitate exploration of novel treatment strategies.
  • Epigenetic regulation offers a promising avenue for modulating oncogenes and tumor suppressors in TNBC.

Purpose of the Study:

  • To review epigenetic drugs (epi-drugs) investigated for the treatment of triple-negative breast cancer.
  • To highlight the role of epi-drugs in targeting epigenetic modifications relevant to TNBC.

Main Methods:

  • Literature review of preclinical and clinical studies on epi-drugs for TNBC.
  • Analysis of epi-drug mechanisms targeting DNA methyltransferases, histone modifiers, and microRNA expression.
  • Investigation of natural and synthetic molecules with epigenetic modulating activities.

Main Results:

  • Epi-drugs represent a developing therapeutic field for TNBC.
  • These drugs target key epigenetic proteins like DNA methyltransferases and histone-modifying enzymes.
  • Modulation of microRNA expression is another mechanism employed by epi-drugs.

Conclusions:

  • Epigenetic therapies offer a novel approach to treating TNBC.
  • Epi-drugs are being actively investigated in preclinical and clinical trials for TNBC.
  • Targeting epigenetic mechanisms holds potential for improving outcomes in TNBC.
Keywords:
DNMT inhibitorsHAT inhibitorsepi-drugshistone deacetylase inhibitorshistone demethylase inhibitorshistone methyltransferase inhibitorsmicroRNAtherapytriple-negative breast cancer

More Related Videos

Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice08:57

Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice

Published on: October 5, 2017

11.3K
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

10.8K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.5K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.6K
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.5K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.6K
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
524
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.8K